HiFiBiO THERAPEUTICS



A Clinical Stage Global Biotech

Transforming the Immunotherapy R&D Paradigm with Single Cell Precision

Major Milestones Achieved Since 2017

*A **clinical-stage** multinational biotech company leveraging proprietary single-cell driven **Drug Intelligence Science, DIS®,** to advance a diverse portfolio of **immunotherapies** for patients*



Experienced Drug Hunters and Developers

Liang Schweizer, PhD
Founder, Chairperson & CEO

HARBOUR BIOMED · Bristol Myers Squibb · SANOFI

Robert Andtbacka, MD, CM
Chief Medical Officer

Seven&Eight Biopharma · University of Utah Huntsman Cancer Institute

Francisco Adrian, PhD
Chief Scientific Officer

NOVARTIS · SANOFI

John Pallante, MS
SVP, Head of Clin. Ops.
& Quality Management

NOVARTIS · Shire

Christos Hatzis, PhD
VP, Head of
Translational Medicine

Bristol Myers Squibb · Yale School of Medicine

Jinping Gan, PhD
VP, Head of Research

VERTEX · Bristol Myers Squibb

Edward Rocnik, PhD
Executive Director,
Head of CMC

Millennium Pharmaceuticals, Inc · Takeda

Jack Pollard, PhD
Executive Director,
Head of Translational Data Science

moderna · SANOFI

Pipeline of Novel Immunotherapies Advancing Through IND and Clinic

Program	Target	Discovery	Preclinical (IND)	Phase I	Phase II/III
HFB200301*	TNFR2 (cancer)				
HFB200603*	BTLA (cancer)				
HFB301001	OX40 (cancer)				
HFB200902	Gal-9 (cancer)	Partnered		FibroGen	
HFB101110	CCR8 (cancer)	Partnered		FibroGen	
HFB200604	BTLA (AID)				
HFB100204	CXCR5 (AID)				
Bispecifics	Novel targets				

Agonist **Antagonist** **Depletor**

**As monotherapy or in combination with anti-PD-1, Tislelizumab, supply agreement with Novartis*

Drug Intelligence Science (DIS®) Opens a New Era for Immunotherapy



L. Schweizer, Drug Discovery Today, Volume 28, Issue 11, Nov. 2023

DIS® is a high-resolution translational platform that aims to enhance the probability of success for drug discovery and development

DIS® Enabled Industry and Academic Strategic Partnerships

	Biopharma	Academic / Government
Target Discovery from patient samples	Kite, A GILEAD Company	Gustave Roussy Cancer Campus Grand Paris
T cell Profiling for neoantigen specific TCRs	Kite, A GILEAD Company	
Antibody Discovery against challenging targets	Pfizer, Janssen, Takeda	Institut Pasteur, Nankai University, DARPA, CoVIC
Biomarker Discovery from single cell analysis		Hôpital Pitié-Salpêtrière AP-HP, institut Curie, UMass Chan Medical School
Out-licensing of DIS® enabled pipeline assets	FibroGen	

Ongoing platform Improvement with Harvard University, Broad Institute, and ESPCI Paris



HiFiBiO THERAPEUTICS

Clinical Stage Oncology Programs

Detailed data on preclinical and clinical activities available under CDA

Cancer Immunotherapies Designed for the Highest Clinical Impact

Targeting difficult to treat tumors and tumors with no or low response to SOCs such as anti-PD-(L)1

Indications	Candidate/MoA	Rationale	Current Status
 **Solid Tumors**	**HFB200301** TNFR2 Agonist First-in-class	• *Modulates innate & adaptive immunity* • *Activates NK and CD8+ T cells*	• **No safety concerns** • **Pharmacology established** • **Promising MoA and biomarker data at single cell level** • **Early efficacy seen**
	HFB301001 OX40 Agonist 2nd Generation	• *Dual T cell + Treg effects* • *No receptor downregulation* • *No interference with OX40L binding*	
	HFB200603 BTLA Antagonist Best-in-class	• *Strong complement to anti-PD-1* • *Dual anti-BTLA & anti-PD-1 for high potency*	

HFB200301 – First-in-Class TNFR2 Agonist

Mechanism of Action



Pre-Clinical Monotherapy Activity



Pre-Clinical Combination Activity



HFB200301 drives TNFR2 activation of CD8+ T cells and Natural Killer cells to achieve antitumor activity in monotherapy or in combination with anti-PD-1

HFB200301 Monotherapy and in Combination with Tislelizumab (anti-PD-1 mAb)



HFB200301 demonstrates excellent tolerability across 5 monotherapy dose cohorts and in combination with tislelizumab, with promising clinical results

NCT05238883

HFB301001 – Best-in-Class Second Generation OX40 Agonist

Mechanism of Action



Pre-Clinical Anti-Tumor Activity



HFB301001 depletes Tregs and activates Teff for superior antitumor activity compared to 1st Gen OX40 agonists

HFB301001 2nd Generation anti-OX40 mAb Monotherapy



- ✓ Trial ongoing
- ✓ No DLTs, MTD not reached
- ✓ Favorable safety profile
- ✓ Promising early clinical results
- ✓ DIS® Immunophenotyping

HFB301001 is well tolerated across 4 dose cohorts in monotherapy with promising clinical results

NCT05229601

HFB200603 – Best-in-Class BTLA Antagonist

Mechanism of Action



Synergistic Activation of Tumor Infiltrating Lymphocytes



HFB200603 blocks HVEM / BTLA immune-suppressive signaling and synergizes with anti-PD-1

HFB200603 Monotherapy and in Combination with Tislelizumab (anti-PD-1 mAb)

Phase I

Phase II

Monotherapy Dose Escalation

- Dose Level 4
- Dose Level 3
- Dose Level 2
- Dose Level 1

Combination Dose Escalation

- Dose Level 4 + tislelizumab
- Dose Level 3 + tislelizumab
- Dose Level 2 + tislelizumab

Combination Dose Expansion

Dose expansion in multiple tumor types

RP2D

Completed / Ongoing

Planned

- ✓ Trial ongoing
- ✓ Safety, PK/PD
- ✓ DIS® Immunophenotyping

HFB200603 in combination with tislelizumab addresses a large unmet need in anti-PD-(L)1 refractory tumors

NCT05789069



HiFiBiO THERAPEUTICS

IND Stage Autoimmune Programs

Additional data on preclinical activities available under CDA

Autoimmune Immunotherapies Designed For the Highest Clinical Impact

Selectively targeting immune cells in autoimmune disease patients with limited therapeutic options

Indications	Candidate/MoA	Rationale	Current Status
 **Autoimmune Diseases**	**HFB200604** BTLA Agonist	• *Suppression of activated T and B cells to restore immune tolerance*	• **IND filing in Q3 2024** • **DIS® translational plan in place**
	HFB100204 CXCR5 Depletor	• *Depletion of Tfh and B cells to block ectopic germinal center formation*	• **Ready for partnership** • **DIS® translational plan in place**

HFB200604 – Best-in-Class BTLA Agonist

Mechanism of Action



Efficacy in Acute GvHD Mouse Model



HFB200604 stimulates BTLA immunosuppressive signals in B and T cells to restore immune tolerance

HFB100204 - Best-in-Class CXCR5 Depletor

Mechanism of Action



Depletion of CXCR5+ B cells

hCXCR5 KI mouse spleen



Sjogren's Syndrome patient blood



HFB100204 selectively depletes CXCR5+ Tfh and B cells and inhibits CXCL13 induced migration to prevent/disrupt the formation of ectopic germinal centers

Transformative Company Focused on Maximizing Clinical Probability of Success



Novel IO drug candidates in Phase I
- TNFR2 first-in-class agonist
- OX40 2nd generation agonist
- BTLA best-in-class antagonist

15M+ single cell database from patient samples with both pre and post SOC
- **35+** tumor types
- **25+** autoimmune diseases

DIS® driven target and drug discovery through AI/ML

8 drug candidates identified
- **4** progressed to phase I
- **2** IO out-licensed
- **2** autoimmune in pre-IND

DIS® driven predictive biomarkers for patient selection through AI/ML

HiFiBiO THERAPEUTICS

Contact Us

Liang Schweizer, Ph.D.
Founder, Chairperson, CEO
l.schweizer@hifibio.com
Profile Link

Robert Andtbacka, MD, CM
CMO
r.andtbacka@hifibio.com
Profile Link

Francisco Adrian, Ph.D.
CSO
f.adrian@hifibio.com
Profile Link

hifibio.com